Title : Inhibition of Methyltransferase DOT1L Sensitizes to Sorafenib Treatment AML Cells Irrespective of MLL-Rearrangements: A Novel Therapeutic Strategy for Pediatric AML.

Pub. Date : 2020 Jul 20

PMID : 32698374






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Inhibition of Methyltransferase DOT1L Sensitizes to Sorafenib Treatment AML Cells Irrespective of MLL-Rearrangements: A Novel Therapeutic Strategy for Pediatric AML. Sorafenib DOT1 like histone lysine methyltransferase Homo sapiens
2 Here, we report that targeting DOT1L with Pinometostat sensitizes pediatric AML cells to further treatment with the multi-kinase inhibitor Sorafenib, irrespectively of MLL-r. DOT1L pharmacologic inhibition induces AML cell differentiation and modulates the expression of genes with relevant roles in cancer development. Sorafenib DOT1 like histone lysine methyltransferase Homo sapiens
3 Through ChIP-seq analysis, we identified the genes regulated by DOT1L irrespective of MLL-r, including the Sorafenib target BRAF, providing mechanistic insights into the drug combination activity. Sorafenib DOT1 like histone lysine methyltransferase Homo sapiens